Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE (NASDAQ: EVO ) ("Evotec") to acquire Evotec for €11.
00 per share in cash, implying a fully diluted equity value of €2.0 billion. The proposal represents a premium of 109% to Evotec's undisturbed share price on October 15, 2024 , the day prior to Triton Partners' initial accumulation of Evotec shares, and a premium of 77% to Evotec's last three-month volume weighted average price on October 15, 2024 .
"The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond," said Helen Torley , president and chief executive officer of Halozyme. "I am excited about the potential to bring together best-in-class innovative technologies and both organizations' capabilities to create a pan U.S.
/ European innovative services company. With increased scale, a deep pipeline, and a diversified offering, we would be a highly attractive strategic partner to the biopharma industry. This in turn would provide a remarkable opportunity to accelerate the discovery and development of medicines that will improve patients' outcomes.
".